COMPANY
Xeris Pharmaceuticals
FDA-approved therapeutic company Clinical Phase 2
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Compensation Analyst | Chicago, IL | Oct 22, 2026 | Oct 7, 2026 |
| Pharmaceutical Sales Representative, Endocrinology (Rare Disease) - Manhattan | REMOTE - New York | Oct 20, 2026 | Oct 21, 2026 |
| Pharmaceutical Sales Representative, Endocrinology (Rare Disease) - Milwaukee | REMOTE - Wisconsin | Oct 19, 2026 | Oct 20, 2026 |
| Vice President, Manufacturing and Engineering | Chicago, IL | Oct 15, 2026 | Oct 5, 2026 |
| Associate Director, CMC Project Management | Chicago, IL | Oct 15, 2026 | Oct 5, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (26 open jobs at last check). source ↗
- Trial start Phase 2: Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism source ↗
- Trial start Phase 2: Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D source ↗
- Trial start 2: Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D source ↗
- Trial start Phase 2: Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery source ↗
- Trial start Phase 3: G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes source ↗
- Trial start Phase 2: Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses source ↗
- Trial start Phase 3: G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes source ↗
- Trial start Phase 3: Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients source ↗
- Trial start Phase 3: Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics source ↗
- Trial start Phase 2: CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism source ↗
- Trial start Phase 2: Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients source ↗
- Trial start Phase 2: G-Pen™ for Hypoglycemia Rescue in T1D Patients source ↗
- Trial start Phase 2: PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients source ↗
- Trial start Phase 2: Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes source ↗
- Trial start Phase 2: Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia source ↗
Open jobs 26
Clinical trials (lead sponsor) 15
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03841526 | Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D | Phase 2 | Completed | Aug 22, 2019 | Apr 2, 2020 (actual) |
| NCT05823012 | Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism | Phase 2 | Completed | May 15, 2023 | Feb 22, 2024 (actual) |
| NCT04074317 | Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D | 2 | Completed | Aug 22, 2019 | Apr 2, 2020 (actual) |
| NCT03490942 | Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses | Phase 2 | Terminated | Mar 15, 2018 | Nov 4, 2019 (actual) |
| NCT03738865 | G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes | Phase 3 | Completed | Sep 27, 2018 | Mar 29, 2019 (actual) |
| NCT03770637 | Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery | Phase 2 | Completed | May 10, 2019 | Feb 26, 2020 (actual) |
| NCT03439072 | G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes | Phase 3 | Completed | Jan 23, 2018 | Apr 18, 2018 (actual) |
| NCT02937558 | CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism | Phase 2 | Completed | 2016-10 | 2018-09 (actual) |
| NCT03091673 | Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients | Phase 3 | Completed | Mar 27, 2017 | Sep 7, 2017 (actual) |
| NCT02733588 | Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients | Phase 2 | Completed | 2016-03 | Apr 5, 2017 (actual) |
| NCT02656069 | Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics | Phase 3 | Completed | Mar 15, 2017 | Aug 14, 2017 (actual) |
| NCT02081001 | PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients | Phase 2 | Completed | 2014-03 | 2014-08 (actual) |
| NCT02081014 | Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes | Phase 2 | Completed | 2014-03 | 2014-11 (actual) |
| NCT02423980 | G-Pen™ for Hypoglycemia Rescue in T1D Patients | Phase 2 | Completed | 2015-04 | 2015-05 (actual) |
| NCT01972152 | Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia | Phase 2 | Completed | 2013-10 | 2014-02 (actual) |
NIH awards 16
- NIH award 5R44NS086229-03 FY2018: $793,851 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Auto-Injectable Diazepam Formulati source ↗
- NIH award 4R44NS086229-02 FY2017: $797,247 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Auto-Injectable Diazepam Formulati source ↗
- NIH award 5R44DK105691-03 FY2017: $754,662 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. CSI Glucagon for Treatment of Cong source ↗
- NIH award 5R44DK107114-03 FY2017: $405,006 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Closed-Loop Glucagon Pump for Trea source ↗
- NIH award 4R44DK105691-02 FY2016: $833,136 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. CSI Glucagon for Treatment of Cong source ↗
- NIH award 4R44DK107114-02 FY2016: $816,080 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Closed-Loop Glucagon Pump for Trea source ↗
- NIH award 1R44NS086229-01A1 FY2015: $514,129 awarded for that fiscal year; activity R44 (SBIR); PI KINZELL, JOHN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Auto-Injectable Diazepam Formulation f source ↗
- NIH award 1R44DK107114-01 FY2015: $561,530 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Closed-Loop Glucagon Pump for Trea source ↗
- NIH award 1R44DK105691-01 FY2015: $485,403 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. CSI Glucagon for Treatment of Cong source ↗
- NIH award 4R44DK096715-02 FY2014: $451,756 awarded for that fiscal year; activity R44 (SBIR); PI KINZELL, JOHN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Glucagon Mini-Dosing Pen for Treatment o source ↗
- NIH award 1R44DK096715-01A1 FY2013: $678,969 awarded for that fiscal year; activity R44 (SBIR); PI KINZELL, JOHN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Glucagon Mini-Dosing Pen for Treatment source ↗
- NIH award 4R44DK096706-02 FY2013: $713,733 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Clinical Development of a Stable G source ↗
- NIH award 5R44DK085809-03 FY2012: $576,491 awarded for that fiscal year; activity R44 (SBIR); PI KINZELL, JOHN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Improved Hypoglycemia Rescue Device source ↗
- NIH award 1R44DK096706-01 FY2012: $343,124 awarded for that fiscal year; activity R44 (SBIR); PI PRESTRELSKI, STEVEN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Clinical Development of a Stable G source ↗
- NIH award 2R44DK085809-02 FY2011: $417,632 awarded for that fiscal year; activity R44 (SBIR); PI KINZELL, JOHN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. Improved Hypoglycemia Rescue Device source ↗
- NIH award 1R43DK085809-01 FY2009: $157,478 awarded for that fiscal year; activity R43 (SBIR); PI KINZELL, JOHN; recipient as written: XERIS PHARMACEUTICALS, INC., CHICAGO, IL. IMPROVED HYPOGLYCEMIA RESCUE DEVICE source ↗
Connect
See your connections at Xeris Pharmaceuticals on LinkedIn (search by name, results not checked)